Istituto Dermopatico dell'Immacolata, Roma Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2006
NCT00832091
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Alternative names

I Divisione di Dermatologia, Istituto Dermopatico dell'Immacolata, IRCCS; Via Monti di Creta 104 - 00167 Roma, Italy | Istituto Dermopatico Dell'Immacolata, Rome , Italy

Active Ingredients

Drugs in Phase 2 Trials (2)

ladarixin (1 trial)

thymosin beta-4 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pemphigoid, Bullous (Phase 2)

Ulcer (Phase 2)

Varicose Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2